Update on current practice in laboratory medicine in respect of natriuretic peptide testing for heart failure diagnosis and management in Europe. The CARdiac MArker guideline Uptake in Europe (CARMAGUE) study
| Autor: | Kari Pulkki, Christopher J. Duff, Paul Collinson, Päivi Laitinen, Sanja Stankovic, Janne Suvisaari, Ana Stavljenić-Rukavina, Angelika Hammerer-Lercher, Michel Langlois, Damien Gruson, Kristin M. Aakre, Hannsjörg Baum |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty medicine.drug_class Clinical Biochemistry Cardiac marker Medical laboratory Natriuretic peptide testing Biochemistry 03 medical and health sciences 0302 clinical medicine Natriuretic Peptide Brain medicine Natriuretic peptide Humans Intensive care medicine Heart Failure business.industry Biochemistry (medical) Confounding General Medicine Guideline medicine.disease Peptide Fragments 3. Good health Europe 030104 developmental biology 030220 oncology & carcinogenesis Heart failure Biomarker (medicine) Laboratories business Biomarkers |
| Zdroj: | Clinica Chimica Acta. 511:59-66 |
| ISSN: | 0009-8981 |
| DOI: | 10.1016/j.cca.2020.09.030 |
| Popis: | Background The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) initiated the CArdiac MARker Guidelines Uptake in Europe (CAMARGUE) Study to survey if current biomarker testing for heart failure (HF) in Europe is in accordance with up-dated guidelines. Methods A web-based questionnaire was distributed to clinical laboratories via European biochemical societies in 2019. Questions covered the type of natriuretic peptide (NP) assays performed, decision limits for HF, and opinion concerning requirement of different thresholds in patients with renal failure or obesity. Results There were 347 participating laboratories mostly from European countries with 266 offering NP testing. NP testing was increased from 67% to 77% between 2013 and 2019. NT-proBNP remained the preferred biomarker. Recommended decision limits were implemented for BNP (85%) and better focused for NT-proBNP (40%) than in the previous survey. The survey revealed that laboratorians are willing to support the translation of adjusted cut-off values for age, gender and for patients with conditions like renal insufficiency. Conclusion Guidelines stimulate clinical laboratories to offer NP testing with high value for the diagnosis and management of HF, and to present adjusted medical decision limits. Future guidelines should encourage the use of personalized cut-offs for some confounding factors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect